Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $100.0 million.

  • ARS Pharmaceuticals' Cash from Financing Activities rose 1461250.0% to $100.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.4 million, marking a year-over-year increase of 520361.92%. This contributed to the annual value of $72.4 million for FY2024, which is 94941.3% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Cash from Financing Activities is $100.0 million, which was up 1461250.0% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Cash from Financing Activities registered a high of $193.8 million during Q4 2022, and its lowest value of -$1.6 million during Q3 2022.
  • Its 5-year average for Cash from Financing Activities is $22.5 million, with a median of $725000.0 in 2025.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 115135.14% in 2022, then skyrocketed by 1461250.0% in 2025.
  • Quarter analysis of 5 years shows ARS Pharmaceuticals' Cash from Financing Activities stood at $52.8 million in 2021, then soared by 266.95% to $193.8 million in 2022, then plummeted by 99.07% to $1.8 million in 2023, then skyrocketed by 3828.86% to $70.9 million in 2024, then surged by 41.08% to $100.0 million in 2025.
  • Its Cash from Financing Activities stands at $100.0 million for Q3 2025, versus $2.7 million for Q2 2025 and $725000.0 for Q1 2025.